• Active, not recruiting

NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in SMM

Updated: Sep 27

NCT02916771: Phase 2: Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

ixazomib smoldering

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.


Sponsor

Dana-Farber Cancer Institute


Collaborators

Celgene

Takeda

 

ClinicalTrials.gov Identifier: NCT02916771

Official Title: Phase II Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

First Posted : September 27, 2016

Click here for details on ClinicalTrials.gov

 

Drug: Ixazomib

Drug: Lenalidomide

Drug: Dexamethasone

 

Location

United States, Massachusetts




Posts Archive